Kornelius S. Schulze

Hamburg, HH 20251, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications

Metabolomics-Enhanced Liquid Biopsy Identifies Early Heptocellular Injury in Females with MetALD.

Metabolomics-Enhanced Liquid Biopsy Identifies Early Heptocellular Injury in Females with MetALD.

Journal: International journal of molecular sciences
Published: March 20, 2026

Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.

Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.

Journal: Gut
Published: November 21, 2025

Targeting a tolerogenic HLA-G genotype to tackle immune evasion and adaptive resistance in HBV-driven HCC.

Targeting a tolerogenic HLA-G genotype to tackle immune evasion and adaptive resistance in HBV-driven HCC.

Journal: JHEP reports : innovation in hepatology
Published: August 19, 2025

Targeting a tolerogenic HLA-G genotype to tackle immune evasion and adaptive resistance in HBV-driven HCC.

Targeting a tolerogenic HLA-G genotype to tackle immune evasion and adaptive resistance in HBV-driven HCC.

Journal: JHEP reports : innovation in hepatology
Published: August 19, 2025

Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).

Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).

Journal: Therapeutic advances in medical oncology
Published: March 31, 2025

Classification of the LC4 Primarily-like Cell Line-Recapitulating a CDK4 Overexpressing Immune Evasive HIV-HCV-Induced HCC.

Classification of the LC4 Primarily-like Cell Line-Recapitulating a CDK4 Overexpressing Immune Evasive HIV-HCV-Induced HCC.

Journal: Viruses
Published: February 24, 2025

Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Journal: Annals of hepatology
Published: January 22, 2025

Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis.

Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis.

Journal: JHEP reports : innovation in hepatology
Published: October 14, 2024

The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study.

The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study.

Journal: The Lancet. Digital health
Published: October 01, 2024

Existential distress in advanced cancer: A cohort study.

Existential distress in advanced cancer: A cohort study.

Journal: General hospital psychiatry
Published: July 19, 2024

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.

Journal: JAMA oncology
Published: July 18, 2024

Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy.

Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy.

Journal: Journal of experimental & clinical cancer research : CR
Published: July 06, 2024
Showing 1-12 of 72

Last Updated: 09/26/2026